



IPO : Molbio Diagnostics Limited

August 2026

Snapshot

Molbio Diagnostics Limited is an Indian molecular diagnostics company engaged in developing, manufacturing, and commercializing innovative diagnostic solutions for infectious diseases, critical care, and other healthcare applications. The company offers integrated platforms comprising diagnostic instruments, reagents, consumables, and software, enabling rapid and accurate testing at the point of care. With multiple manufacturing facilities, strong research and development capabilities, and a growing domestic and international presence, Molbio focuses on improving access to affordable, high-quality diagnostics. The company's proposed IPO comprises a fresh issue and an offer for sale, aimed at supporting future growth and enhancing its market position.

Company Vision

Molbio Diagnostics Limited's vision is to transform healthcare through accessible, affordable, and innovative molecular diagnostic solutions that enable early and accurate disease detection. The company seeks to expand its leadership in point-of-care diagnostics by leveraging continuous research, technological innovation, and high-quality manufacturing capabilities. It aims to improve patient outcomes by delivering rapid diagnostic platforms that address critical healthcare needs across both developed and emerging markets. By strengthening its global presence, expanding its product portfolio, and fostering scientific excellence, Molbio aspires to make advanced molecular diagnostics widely available while contributing to better public health and sustainable long-term value creation.

Growth Prospects

Molbio Diagnostics Limited's growth prospects are supported by the increasing adoption of molecular diagnostics, rising demand for rapid point-of-care testing, and expanding healthcare infrastructure across domestic and international markets. The company is well positioned to benefit from its strong research and development capabilities, diversified portfolio of diagnostic platforms, and integrated manufacturing facilities. It also intends to strengthen its global footprint through new product launches, geographic expansion, and deeper penetration into existing markets. Continued investment in innovation, strategic partnerships, and advanced diagnostic technologies is expected to enhance its competitive position and support sustainable long-term growth.

Opening Date	Monday, August 10, 2026
Closing Date	Wednesday, August 12, 2026
Price Band	Rs. 768 to 807 per share
Bid Lot	18 Shares
Issue Size	1,16,46,246 shares (aggregating up to Rs. 940 Cr)
Fresh Issue	24,80,246 shares (aggregating up to Rs. 200 Cr)
Offer for Sale	91,66,000 shares (aggregating up to Rs. 740 Cr)
Registrar	Kfin Technologies Ltd.

Key Financials

Amount in cr.	FY2026	FY2025	FY2024
Assets	2,148	1,462	1,221
Total Income	1,455	1,028	841
Profit After Tax	164	139	84
EBITDA	328	257	185
NET Worth	1,145	953	808
Reserves and Surplus	1,149	991	845
Total Borrowing	413	123	175

Risk Assessment

Molbio Diagnostics Limited faces risks associated with regulatory approvals, product quality compliance, and the highly competitive molecular diagnostics industry. Its business depends on continuous innovation, successful commercialization of new products, and maintaining technological leadership in a rapidly evolving market. The company is also exposed to supply chain disruptions, fluctuations in raw material availability, and dependence on key customers and distribution networks. Expansion into international markets may involve regulatory, operational, and geopolitical challenges. Additionally, changes in healthcare policies, reimbursement frameworks, and pricing pressures could impact profitability.